Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar versions currently approved, researchers found.
All News
Article
Article
Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!
Article
A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO.
Dr. Antoni Chan
Tweet
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek
National Psoriasis Foundation’s 2019 Annual Survey of 1,570 #PSO pts found among 801 w/ PsA most (59.6%) report unacceptable levels of disease activity, which is associated with increased prevalence of depression and limitations in social participation. https://t.co/HtWcAhZ6Zu https://t.co/pdC4IjIxmj
Israeli study shows the prevalence of Psoriatic arthritis has tripled since 2006
- 2006: 0.073%
- 2016: 0.165%
- 2022: 0.221%
~2 fold higher rate if Jewish, High SES, Obese
https://t.co/RMWcIZvfjb https://t.co/9H6sauSEZK https://t.co/Fhj64pADdJ
Full read review on Psoriasis Flares; risks:
- mechanical stress
- infections
-dysbiosis
-drugs (Lithium, B-blockers, HCQ, tetracyclines, ACEi, IFN)
- environment(smoking, obesity)
-lifestyle
- stress
- hormonal/metabolic https://t.co/WfCzcG9XNM https://t.co/ZNeKxjtHSA https://t.co/sJDoSfFOL4
Study of 150 #PsA pts & Aortic stiffness (carotid-femoral pulse wave velocity (cfPWV) - cfPWV signif higher in PsA vs controls (p=0.034). , cfPWV assoc w/ Dz duration (r=0.3), systolic BP, GFR, RDW. cfPWV was superior to SCORE (16% vs 8.7%) at CV risk https://t.co/H6SbsIdXw0 https://t.co/Yt19QCk9TT
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO.
https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw
Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp
Biomarkers Predictive of a Deucravacitinib Response in PsA
A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in PsA suggests specific biologic effects identified by biomarkers may predict clinical responses.
https://t.co/zsZl7JQydn https://t.co/4mGBYB4qU4
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/9t41cjROwW https://t.co/9AelBwoRzs
Window of Opportunity in Psoriatic Arthritis
The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome.
https://t.co/eUL1wzrXVt https://t.co/XSETW2zpGs
